Jonathan Wolleben
Stock Analyst at JMP Securities
(4.44)
# 341
Out of 4,981 analysts
217
Total ratings
53.85%
Success rate
18.64%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Market Outperform | $27 → $28 | $14.01 | +99.86% | 5 | Sep 12, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Outperform | $483 → $485 | $432.27 | +12.20% | 13 | Aug 20, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Market Outperform | $18 | $3.93 | +358.02% | 13 | Aug 19, 2025 | |
| PHVS Pharvaris | Maintains: Market Outperform | $55 → $52 | $23.38 | +122.41% | 12 | Aug 13, 2025 | |
| ATXS Astria Therapeutics | Maintains: Market Outperform | $25 → $26 | $7.43 | +249.93% | 3 | Aug 13, 2025 | |
| QNCX Quince Therapeutics | Maintains: Market Outperform | $9 → $8 | $1.60 | +400.00% | 2 | Aug 12, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Market Outperform | $90 → $86 | $34.00 | +152.94% | 15 | Aug 11, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Market Outperform | $67 → $69 | $58.82 | +17.31% | 12 | Aug 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Market Outperform | $79 → $81 | $74.31 | +9.00% | 11 | Aug 7, 2025 | |
| GPCR Structure Therapeutics | Maintains: Market Outperform | $89 → $87 | $20.91 | +316.07% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $130 → $135 | $96.22 | +40.30% | 4 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $15 | $3.64 | +312.09% | 13 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $2.19 | +265.30% | 8 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $21 | $9.87 | +112.77% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $15 | $4.25 | +252.94% | 3 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $6.18 | +207.44% | 9 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.32 | +1,464.95% | 11 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $38 | $10.83 | +250.88% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $22 → $19 | $12.81 | +48.32% | 17 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $7.91 | +127.56% | 8 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.55 | +153.52% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $45.21 | +10.60% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $86.80 | +3.69% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $122.55 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $696.40 | -30.36% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $6.76 | +373.37% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.60 | +1,231.56% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $33.62 | -28.61% | 1 | May 12, 2023 |
KalVista Pharmaceuticals
Sep 12, 2025
Maintains: Market Outperform
Price Target: $27 → $28
Current: $14.01
Upside: +99.86%
Madrigal Pharmaceuticals
Aug 20, 2025
Maintains: Market Outperform
Price Target: $483 → $485
Current: $432.27
Upside: +12.20%
Larimar Therapeutics
Aug 19, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $3.93
Upside: +358.02%
Pharvaris
Aug 13, 2025
Maintains: Market Outperform
Price Target: $55 → $52
Current: $23.38
Upside: +122.41%
Astria Therapeutics
Aug 13, 2025
Maintains: Market Outperform
Price Target: $25 → $26
Current: $7.43
Upside: +249.93%
Quince Therapeutics
Aug 12, 2025
Maintains: Market Outperform
Price Target: $9 → $8
Current: $1.60
Upside: +400.00%
Crinetics Pharmaceuticals
Aug 11, 2025
Maintains: Market Outperform
Price Target: $90 → $86
Current: $34.00
Upside: +152.94%
Protagonist Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $67 → $69
Current: $58.82
Upside: +17.31%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Market Outperform
Price Target: $79 → $81
Current: $74.31
Upside: +9.00%
Structure Therapeutics
Aug 7, 2025
Maintains: Market Outperform
Price Target: $89 → $87
Current: $20.91
Upside: +316.07%
Aug 6, 2025
Maintains: Market Outperform
Price Target: $130 → $135
Current: $96.22
Upside: +40.30%
Jul 10, 2025
Maintains: Market Outperform
Price Target: $25 → $15
Current: $3.64
Upside: +312.09%
Jun 27, 2025
Reiterates: Market Outperform
Price Target: $8
Current: $2.19
Upside: +265.30%
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $21
Current: $9.87
Upside: +112.77%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $4.25
Upside: +252.94%
May 23, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $6.18
Upside: +207.44%
May 16, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.32
Upside: +1,464.95%
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $10.83
Upside: +250.88%
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $12.81
Upside: +48.32%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.91
Upside: +127.56%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.55
Upside: +153.52%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $45.21
Upside: +10.60%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $86.80
Upside: +3.69%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $122.55
Upside: -
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $696.40
Upside: -30.36%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $6.76
Upside: +373.37%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.60
Upside: +1,231.56%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $33.62
Upside: -28.61%